US Material Events SEC 8-K Filings — April 21, 2026

21-04-2026

SoundHound AI, Inc. (Nasdaq: SOUN) announced a definitive agreement to acquire LivePerson, Inc. (Nasdaq: LPSN) for an equity value of $43M (22% premium), implying a $250M enterprise value after receiving $74M cash and retiring debt, resulting in a debt-free combined company with a $500M revenue opportunity from the existing customer base. The deal combines SoundHound's voice AI with LivePerson's digital messaging, serving 25 Fortune 100 companies and expanding omnichannel capabilities across key verticals. While forward-looking benefits are highlighted, risks include integration challenges, regulatory approvals, and potential failure to realize synergies.

• ·Transaction expected to close in second half of 2026, subject to regulatory approvals and LivePerson stockholder approval.
• ·Combined customers include 12 of top 15 global banks, 4 of top 5 global airlines, 4 of top 5 global automakers, 10+ leading telecom providers.
• ·SoundHound's fifth strategic acquisition, following Amelia and Interactions.
• ·Advisors: Barclays and Latham & Watkins (SoundHound); Lazard and Fried, Frank, Harris, Shriver & Jacobson (LivePerson).

21-04-2026

Rigetti & Co, LLC, a wholly-owned subsidiary of Rigetti Computing, Inc., entered into a sublease agreement on April 17, 2026, for approximately 12,543 rentable square feet of office and laboratory space at 740 Heinz Avenue, Berkeley, California, from Chinook Therapeutics, Inc. The sublease term commences on the later of June 1, 2026, master landlord consent, and delivery of premises, expiring November 30, 2029, with monthly base rent starting at $38,111.91 and escalating annually to $41,645.91 by year four, plus an 11.19% proportionate share of taxes, insurance, and operating expenses, and a $50,000 security deposit. The agreement is subject to consent from the master landlord, Seventh Street Properties VII, LLC, within 60 days, or it may be terminated.

• ·Sublease rent payable in advance on the first day of each month starting from Commencement Date
• ·Sublease effectiveness contingent on Master Landlord consent within 60 days of April 17, 2026, or terminable by either party
• ·Portion of master lease totaling 112,088 rentable square feet from September 11, 2015

21-04-2026

NeoVolta Inc. amended agreements for its joint venture NeoVolta Power, LLC, removing NPJV MANAGER LLC as a member, increasing NeoVolta's authorized Class A Units to 80 and reducing Can Current Corporation's (CCC) Class B Units to 20, with NeoVolta designating all three Board managers. NeoVolta Power entered an Asset Purchase Agreement to acquire battery manufacturing equipment from CCC for $9,000,000 payable in milestone installments of $2,000,000, $3,000,000, and $4,000,000, plus tariffs. NeoVolta also issued 1,200,000 shares of common stock to PotiSedge Technology Pte Ltd. for sales and marketing services, vesting semi-annually over 24 months.

• ·Management Services Agreement effective April 20, 2026, with 24-month initial term and termination provisions for breach.
• ·Share Grant to PotiSedge retains voting/dividend rights on unvested shares; repurchase at $0.001 per share upon forfeiture.
• ·CCC granted right to designate up to two non-voting observers to NeoVolta Power Board meetings.
• ·Agreements filed as Exhibits 10.1 (A&R Operating Agreement), 10.2 (First Amendment to Contribution Agreement), 10.3 (Asset Purchase Agreement), 10.4 (Management Services Agreement).

21-04-2026

JATT II Acquisition Corp, a blank check SPAC targeting healthcare and biotechnology sectors, announced the pricing of its $60,000,000 initial public offering of 6,000,000 ordinary shares at $10.00 per share, expected to begin trading on Nasdaq under ticker 'JATT' on April 17, 2026, with closing on April 20, 2026. Guggenheim Securities, LLC serves as sole book-running manager, with a 45-day option for underwriters to purchase up to 900,000 additional shares for over-allotments. The SEC declared the registration statement effective on April 16, 2026.

• ·Company sponsored by JATT Ventures II L.P. and focused on healthcare, biotechnology, life sciences, with emphasis on data-driven approaches like machine learning and computational biology.
• ·SEC registration statement declared effective on April 16, 2026.
• ·No specific business combination target selected as of announcement.

21-04-2026

Delek US Holdings, Inc. announced the appointment of Amber Russell as Executive Vice President, Refining, effective April 20, 2026, succeeding Joseph Israel, who is departing after contributions to operational excellence. Ms. Russell brings nearly three decades of experience from ExxonMobil and bp, including senior roles in refining, terminals, and pipelines. Avigal Soreq, President and CEO, highlighted her expertise as key to strengthening Delek's refining platform.

• ·Ms. Russell will be based at Delek’s Brentwood, Tennessee office and report directly to Avigal Soreq.
• ·Announcement dated April 20, 2026; SEC filing April 21, 2026.

21-04-2026

Onto Innovation announced a strategic partnership with Rigaku to advance X-ray process control solutions for advanced V-NAND, DRAM, logic, and memory, integrating its Ai Diffract™ software with Rigaku’s CD-SAXS platforms, which has been selected by two key customers targeting a market estimated in excess of $1 billion within five years. The company entered a definitive agreement to acquire 27% of Rigaku’s outstanding common stock for $710 million from an affiliate of The Carlyle Group, gaining board nomination rights, with the deal expected to close in H2 2026 and be accretive by December 31, 2026. No declines or flat metrics reported.

• ·Transaction subject to customary closing conditions including regulatory approvals
• ·Onto Innovation to account for investment under fair value option method without consolidation
• ·Right to nominate one director to Rigaku’s board upon closing
• ·Expected closure in second half of 2026
• ·Advisors: Greenhill (financial), Goldman Sachs (financing), Simpson Thacher & Bartlett LLP and Nishimura & Asahi (legal) for Onto

21-04-2026

CrowdStrike's Board approved a performance- and service-based equity award of 100,000 target PSUs to President Michael Sentonas under the 2019 Equity Incentive Plan, tied to the company's TSR relative to S&P 500 companies over a three-year period from December 22, 2025, to December 22, 2028, with potential payout from 0 to 200,000 shares based on percentile rankings (50% at 25th percentile threshold, 200% at 90th+). The award recognizes Sentonas's role in driving revenue growth from $3.06B in FY2024 to $4.81B in FY2026 and ARR from $3.44B to $5.25B, alongside a 300% stock return ranking in the 95th percentile of S&P 500 over three years. It aligns incentives with the ambition to reach $20B in ending ARR amid expansions in high-growth markets and strategic acquisitions.

• ·PSU payout levels: 200% at 90th+ percentile TSR, 150% at 75th, 100% at 55th, 50% at 25th, 0% below 25th
• ·Earned PSUs subject to additional one-year service vesting (25% quarterly on Mar 20, Jun 20, Sep 20, Dec 20, 2029)
• ·Performance period: December 22, 2025 to December 22, 2028
• ·Award approved April 16, 2026

21-04-2026

Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced the pricing of an underwritten public offering of 18,018,014 shares of common stock at $4.44 per share and pre-funded warrants to purchase up to 2,252,252 shares at $4.4399 per warrant, expecting gross proceeds of approximately $90.0 million before expenses. The offering, led by new investor RA Capital Management with participation from Soleus Capital and others, is anticipated to close on or about April 21, 2026, with net proceeds allocated to general corporate purposes including research, preclinical, and clinical development of product candidates. No declines or flat metrics were reported in this financing announcement.

• ·Registration statement on Form S-3 filed with SEC on May 30, 2024, declared effective June 10, 2024.
• ·Offering joint book-running managers: Goldman Sachs & Co. LLC, Evercore ISI, Citizens Capital Markets.

21-04-2026

Brady Corporation (NYSE: BRC) has entered a definitive agreement to acquire Honeywell’s Productivity Solutions and Services (PSS) business for $1.4 billion in cash, at approximately 8x EBITDA for the twelve months ended December 31, 2025. PSS generated approximately $1.1 billion in sales in 2025 with about 3,000 employees globally, and the acquisition is expected to be double-digit accretive to adjusted diluted EPS within the first year, with minimum $25 million in annual run-rate cost synergies within three years. The deal expands Brady's addressable market into the $9 billion productivity solutions sector and is anticipated to close in the second half of 2026, subject to regulatory approvals.

• ·Transaction funded with cash on hand and new debt financing; expected net debt-to-EBITDA of 2.5x post-transaction, deleveraging to below 2.0x within two years
• ·PSS based in Fort Mill, South Carolina, with operations in North America, Europe, Latin America, and Asia
• ·Conference call held April 20, 2026, at 8:30 a.m. ET; presentation materials on Brady’s investor website
• ·Unanimously approved by boards of both companies; subject to regulatory approvals and customary closing conditions

21-04-2026

On April 20, 2026, Eduardo Martins, M.D., D.Phil., retired as Chief Medical Officer of Sagimet Biosciences Inc., effective immediately, and will continue as an external scientific advisor. The company appointed Andreas Grauer, M.D., as the new Chief Medical Officer, effective the same date. Dr. Grauer previously served as CMO at Omeros Corporation (October 2023 to April 2026), Federation Bio (October 2021 to July 2023), and Corcept Therapeutics (March 2019 to August 2021), with prior roles at Amgen and Procter & Gamble Pharmaceuticals.

• ·Dr. Grauer held Vice President Global Development role at Amgen from December 2008 to December 2018.
• ·Dr. Grauer is an Associate Professor of Medicine at the University of Heidelberg Medical School.
• ·Series A Common Stock has $0.0001 par value per share and trades as SGMT on Nasdaq Global Market.

21-04-2026

Sow Good Inc. (SOWG) announced a transformative acquisition of the Nachu Graphite Project in Tanzania from Ryzon Materials Ltd for AUD$150M (approx. $107M USD) in shares, gaining a reported 174Mt mineral resource, 76Mt ore reserve, and potential 236,000 tpa graphite concentrate production at 98.5%-99.0% purity, with a binding offtake from a Tier-1 EV manufacturer. The deal positions the company as a critical minerals developer alongside its freeze-dried treats business, but all technical and economic data from the 2022 JORC BFS is unverified by Sow Good, not S-K 1300 compliant, and subject to re-verification. The transaction requires stockholder approval, Tanzanian regulatory clearances, and other conditions, with no assurance of closing.

• ·Project fully permitted with Special Economic Zone license and 15.5-year mine life.
• ·Binding offtake agreement with U.S. Tier-1 EV/ESS manufacturer; terms and status unverified.
• ·Closing conditions include Nasdaq Rule 5635 stockholder approval, Tanzanian FCC/Mining Commission approvals, no material adverse change.
• ·Consideration shares subject to lock-up, dribble-out, and registration rights.
• ·Escrow via 222,767 contingent value rights releasing shares at 12- and 18-month indemnification milestones.
• ·10-day VWAP US$0.3209; AUD/USD 0.7149 as of announcement.

21-04-2026

AXT, Inc. announced its intention to conduct a public offering of common stock, subject to market conditions, with underwriters granted a 30-day option to purchase up to an additional 15% of the shares. Net proceeds will primarily support the capacity expansion of its subsidiary Beijing Tongmei Xtal Technology Co., Ltd. for indium phosphide substrates, along with R&D, working capital, and general corporate purposes. Northland Capital Markets serves as sole bookrunner, with Needham & Company, B. Riley Securities, Inc., Craig-Hallum Capital Group LLC, and Wedbush Securities Inc. as co-managers; a shelf registration on Form S-3ASR was filed with the SEC on April 20, 2026.

• ·Manufacturing facilities in three locations in China; partial ownership in ten Chinese raw materials companies.
• ·End markets: 5G infrastructure, data center connectivity (silicon photonics), passive optical networks, LED lighting, lasers, sensors, power amplifiers for wireless devices, satellite solar cells.
• ·Headquarters: Fremont, California (worldwide); Beijing, China (Asia).
• ·Shelf registration: Form S-3ASR filed April 20, 2026; preliminary prospectus supplement available on SEC website.

21-04-2026

The Simply Good Foods Company announced on April 20, 2026, that Ms. Amy Held, Senior Vice President and Chief Human Resources Officer and a named executive officer, will depart by June 1, 2026, as part of several corporate realignment initiatives. In connection with her departure, Ms. Held will receive benefits under the Company's Third Amended and Restated Executive Severance Plan, and the Compensation Committee accelerated the vesting of her 6,881 time-based Restricted Stock Units to June 1, 2026.

• ·Date of earliest event reported: April 17, 2026
• ·Form 8-K filing date: April 21, 2026

21-04-2026

Modular Medical, Inc. (NASDAQ:MODD) announced the pricing of a registered direct offering of 750,000 shares of common stock at $4.50 per share, expected to generate gross proceeds of approximately $3.4 million before fees and expenses. The offering is expected to close on or about April 21, 2026, with Maxim Group LLC acting as the sole placement agent. No other comparative financial metrics were provided in the announcement.

• ·Shelf registration statement on Form S-3 (File No. 333-287313) declared effective by SEC on May 22, 2025.
• ·Press release dated April 19, 2026; 8-K filing dated April 21, 2026.

21-04-2026

Bassett Furniture Industries, Inc. (BSET) announced on April 21, 2026, that Bruce Cohenour, SVP-Chief Sales Officer, will retire effective May 31, 2026. No successor was named in the filing. The announcement was made via Form 8-K under Item 5.02.

• ·The Form 8-K was signed by J. Michael Daniel on April 21, 2026.

21-04-2026

ENIGMA-BULWARK, LTD reported that Board Member Mr. Phil Woolas ceased to serve effective March 16, 2026, due to his death, expressing great sadness over the loss of his guidance and contributions. The company noted his extensive background in UK politics, government, and security-related roles. No family relationships exist between Mr. Woolas and other officers or directors.

• ·Phil Woolas previously oversaw UK Border Agency with 120,000 staff and was responsible for portfolios including Local Government funding (circa £130 billion), Immigration Policy, and Civil Contingency Planning.
• ·The filing was signed by Calli Bucci, Chief Financial Officer, on April 20, 2026.

21-04-2026

Goldman Sachs Private Credit Corp. entered into a Sixth Supplemental Indenture with Computershare Trust Company for the issuance of $750,000,000 aggregate principal amount of 6.150% notes due June 16, 2031. The Notes Offering closed on April 21, 2026, yielding net proceeds of approximately $732.55 million, to be used for repaying a portion of outstanding credit facility indebtedness and general corporate purposes. The notes are general unsecured senior obligations with semi-annual interest payments starting December 16, 2026, subject to covenants including asset coverage requirements and change of control repurchase provisions.

• ·Notes may be redeemed at Company's option at prices set forth in the Indenture.
• ·Company entered into a Registration Rights Agreement obligating it to file a registration statement for an exchange offer or shelf registration, with additional interest penalties for delays.
• ·Notes rank senior to subordinated debt, pari passu with other unsecured unsubordinated debt, effectively junior to secured debt, and structurally junior to subsidiary indebtedness.

21-04-2026

On April 21, 2026, Virgin Galactic Holdings, Inc. and Galactic Co., LLC amended employment agreements with CFO and Treasurer Douglas Ahrens and Chief People Officer and Executive Vice President, Astronaut Operations Aparna Chitale. The amendments entitle executives to any earned but unpaid prior-year annual bonus upon qualifying termination and, upon qualifying termination within 24 months post-change in control, increase Mr. Ahrens' cash severance multiplier from 1.0 to 1.5 while extending Company-subsidized healthcare coverage for both from 12 to 18 months. No financial performance metrics or other impacts are disclosed.

• ·Qualifying termination defined as Company termination without 'cause' or executive resignation for 'good reason'.
• ·Amendments filed as Exhibits 10.1 (Ahrens) and 10.2 (Chitale).

21-04-2026

Voyager Therapeutics, Inc. announced that Nathan Jorgensen, Ph.D., resigned as Chief Financial Officer effective May 8, 2026, to pursue a new opportunity, with no disagreements with the company. In connection, the board appointed Robin Swartz, current Chief Operating Officer and Chief Business Officer, as principal financial officer and treasurer, and Amy Quinlan, Vice President of Finance, as principal accounting officer, both effective May 8, 2026.

• ·Resignation notified on April 15, 2026; board appointments on April 20, 2026.
• ·Robin Swartz, age 55; previously at Sanofi Genzyme in senior roles.
• ·Amy Quinlan, age 51; no family relationships or disclosable transactions under Item 404(a) for either appointee.

21-04-2026

CoreWeave, Inc. (Nasdaq: CRWV) announced its intention to offer $1,000 million aggregate principal amount of 9.750% senior notes due 2031 in a private offering, subject to market conditions. These notes will be additional under the April 14, 2026 Indenture, following the prior issuance of $1,750 million of the same notes, and guaranteed by certain wholly-owned subsidiaries. Proceeds are intended for general corporate purposes, including repayment of outstanding indebtedness and related fees.

• ·Notes offered only to qualified institutional buyers under Rule 144A or non-U.S. persons under Regulation S; not registered under Securities Act.
• ·Company established in 2017; completed Nasdaq public listing (CRWV) in March 2025.
• ·Forward-looking statements subject to risks including market conditions and ability to complete offering.

21-04-2026

On April 18, 2026, Randolph C. Read, a director of SandRidge Energy, Inc., notified the company that he will not stand for re-election to the Board of Directors at the 2026 Annual Meeting of Stockholders and will continue serving until the expiration of his current term. Mr. Read's decision was not due to any disagreement with the company's operations, policies, or practices. No other changes to the board or officer positions were reported.

• ·SandRidge Energy, Inc. trades on the New York Stock Exchange under ticker SD (Common Stock, $0.001 par value).

21-04-2026

NEXGEL, Inc. closed its license and acquisition of Celularity Inc.'s portfolio of 6 commercial-stage regenerative biomaterial products for degenerative diseases, financed by a $5.5 million convertible note led by Sequence LifeScience™. The transaction is expected to approximately triple NEXGEL’s annual revenue to $35 million on a pro-forma basis and be immediately accretive to profitability, with the launch of BioNX Surgical division. Sequence LifeScience™ will serve as contract manufacturer, with plans for three new product 510(k) filings in 2026, 2027, and 2028.

• ·Convertible note terms: $0.60 conversion price, 50% warrant coverage with $0.80 strike price.
• ·Shareholder update call: April 21, 2026 at 4:30 P.M. ET (1-800-267-6316 US Toll Free or 1-203-518-9783 International; webcast available).
• ·Acquired products focused on tendon repair, soft tissue reconstruction, and bone regeneration with over a decade of clinical use.

21-04-2026

Spyros Papapetropoulos resigned from Lipocine Inc.'s Board of Directors effective April 16, 2026, where he had served as Chairman, Lead Independent Director, and compensation committee member since 2022, due to competing professional commitments and differing views on the company's strategic direction. The Board appointed R. Dana Ono as the new Chairman and Lead Independent Director on April 20, 2026. No financial or operational impacts from the changes were disclosed.

21-04-2026

Eli Lilly and Company notified Rigel Pharmaceuticals, Inc. on April 16, 2026, of its election to terminate the License and Collaboration Agreement dated February 18, 2021, covering ocadusertib (previously R552) and other RIPK1 inhibitors for non-CNS and CNS diseases, with termination effective June 15, 2026. Rigel will regain full rights to the licensed compounds post-termination, providing potential for independent development. However, following this and the prior CNS program termination in November 2025, Rigel expects no future milestone payments or royalties under the agreement.

• ·Agreement granted Lilly exclusive worldwide license for non-CNS diseases and collaboration on CNS diseases.
• ·Rigel is evaluating the impact of the termination.

21-04-2026

On April 16, 2026, Andreas Roellgen ceased serving as Executive Vice President and President of the Engineered Bearings business segment at The Timken Company, effective close of business that day. Timothy A. Graham has assumed interim leadership of the segment, with an external search launched for a permanent successor. The filing notes Mr. Roellgen's European domicile may require local legal processes, potentially leading to an amended 8-K.

• ·Filing submitted on April 21, 2026
• ·Company headquartered at 4500 Mt. Pleasant St. NW, North Canton, OH 44720

21-04-2026

Horizon Space Acquisition II Corp. entered into a promissory note for US$50,000 with its sponsor, Horizon Space Acquisition II Sponsor Corp., dated April 20, 2026, as disclosed in an 8-K filing on April 21, 2026. The interest-free note matures upon consummation of a Business Combination or the company's term expiry and is convertible into private units at $10.00 per unit. No period-over-period financial comparisons or performance metrics are provided in the filing.

• ·Promissory note provides conversion rights into private units upon written notice at least two business days prior to Business Combination closing
• ·No fractional units issued; cash paid in lieu for fractions
• ·Default interest on overdue amounts at prevailing short-term US Treasury Bill rate
• ·Governed by New York law; payee waives claims against Trust Account Funds
• ·Prospectus reference: File No. 333-282758

21-04-2026

Eric R. Ray, Senior Executive Vice President and Chief Digital Officer of Radian Group Inc., provided notice on April 20, 2026, of his decision to retire from the company effective July 1, 2026. His retirement is not due to any disagreement with the company's operations, policies, or practices. The announcement was filed on April 21, 2026.

• ·Company address: 550 East Swedesford Road, Suite 350, Wayne, Pennsylvania, 19087
• ·Common Stock trading symbol: RDN on New York Stock Exchange

21-04-2026

CAVA Group, Inc. announced that Board member Karen Kochevar will retire upon the expiration of her current term and will not stand for re-election at the 2026 Annual Meeting, concluding her 10 years of service including the company's transition from private to public. The decision is part of the Board's ongoing succession planning process. CEO Brett Schulman thanked Ms. Kochevar for her significant contributions during a period of substantial growth and development.

• ·Filing items: 5.02 (Departure of Directors or Certain Officers), 9.01 (Financial Statements and Exhibits)
• ·Annual Meeting reference: 2026
• ·Media Contact: cava@media.com

21-04-2026

Firefly Aerospace Inc. entered into confirmatory employment letter agreements on April 16, 2026, with executives Jason Kim ($500,000 base salary, 100% bonus target), Darren Ma ($420,000 base salary, 60% bonus target), and Ramon Sanchez ($425,000 base salary, 50% bonus target), superseding prior agreements and including eligibility for company benefit plans and restrictive covenants. On April 15, 2026, the Board approved clarifying amendments to the Executive Severance Plan, and the executives entered participation agreements to become eligible for its benefits. The agreements are filed as Exhibits 10.1 through 10.4.

• ·Filing date: April 21, 2026; Earliest event date: April 15, 2026
• ·Common stock trading symbol: FLY; Par value: $0.0001 per share
• ·Registrant is an emerging growth company

21-04-2026

Dr. Jeffrey Sherman, a director of Xeris Biopharma Holdings, Inc. since 2021 and member of the Compensation Committee and Nominating and Corporate Governance Committee, provided notice on April 20, 2026, of his retirement from the Board and decision not to stand for reelection at the 2026 Annual Meeting. The Board approved a reduction in its size from eight to seven directors effective upon expiration of Dr. Sherman's term. His departure was not due to any disagreement with the Company on operations, policies, or practices.

• ·Dr. Sherman has served on the Compensation Committee and Nominating and Corporate Governance Committee.
• ·The 8-K was filed on April 21, 2026.

21-04-2026

ENZON PHARMACEUTICALS, INC. (ENZN) filed an 8-K on April 21, 2026, disclosing Exhibit 10.1: the Seventh Amendment to Credit Agreement dated April 16, 2026, for Viskase Companies, LLC (Borrower), subsidiary guarantors, lenders, and Bank of America, N.A. as Administrative Agent, amending the original Credit Agreement from October 9, 2020. The amendment requires payment of a $682,000 Seventh Amendment Fee, fully earned and non-refundable upon effectiveness, along with other closing conditions such as no Default or Event of Default, officer's certificates, and legal opinions. All obligations under the Loan Documents are reaffirmed, with a general release of claims by the Loan Parties.

• ·Amendment effective upon satisfaction of closing conditions including executed amendment by all parties, officer’s certificates, good standing certificates, legal opinion from Jenner & Block LLP, and payment of fees/expenses to McGuireWoods LLP and Ankura Consulting Group, LLC.
• ·Loan Parties provide general release of all claims against Administrative Agent, Lenders, and affiliates related to the Credit Agreement and Loan Documents.

21-04-2026

National Health Investors, Inc. (NHI) announced the sale of its portfolio of 32 skilled nursing facilities and three independent living facilities to National HealthCare Corporation (NHC) for $560.0 million, expected to close on July 1, 2026, generating net proceeds after $6.0-$8.0 million in costs but resulting in the loss of $39.7 million in 2025 cash lease revenue from these 35 properties. The transaction strengthens the balance sheet with pro forma net debt-to-annualized EBITDA at 2.3x and $1.4 billion in liquidity, while increasing SHOP concentration to 22.0% of total investments (13.8% of NOI) and reducing SNF exposure to 12.2% of investments (16.5% of NOI).

• ·Transaction approved by Special Committee of Non-Interested Directors.
• ·Subject to Hart-Scott-Rodino Antitrust waiting period expiration.
• ·Investor presentation available on NHI website.

21-04-2026

Abacus Global Management, Inc. (NYSE: ABX) announced key leadership appointments effective April 17, 2026, including Alexei Solomon as Chief Accounting Officer and Treasurer, and Elena Plesco as Chief Investment Officer, both internal promotions reflecting organizational growth. Samantha Butcher will continue as President of Abacus Life Solutions, and Bill McCauley as Chief Financial Officer and Chief Operating Officer. CEO Jay Jackson praised the team's expertise and commitment.

• ·Alexei Solomon has over 20 years of accounting and finance experience, previously Director of SEC Reporting & Technical Accounting at Abacus.
• ·Elena Plesco has over 15 years of finance and investing experience, previously Chief Capital Officer at Abacus and Co-Head of Specialty Finance at KKR.
• ·Samantha Butcher has been with Abacus for over 20 years.
• ·Investor Relations contacts: Robert F. Phillips (rob@abacusgm.com, (321) 290-1198); David Jackson (david@abacusgm.com, (321) 299-0716).

21-04-2026

Envoy Medical, Inc. appointed Charles S. McKhann as a Class I director effective April 15, 2026, increasing the Board size from six to seven members; he was also appointed to the Compensation Committee. Mr. McKhann brings extensive medical device experience, including as CEO of Silk Road Medical and Apollo Endosurgery (both acquired by Boston Scientific), and current roles at Exagen, Inc. and Distalmotion SA. He received stock options to purchase 100,000 shares of Class A Common Stock at $0.72 per share, vesting over 36 months, and qualifies as an independent director with no related party transactions.

• ·Stock options vest in 36 equally monthly installments.
• ·Mr. McKhann's initial term expires at the 2027 annual meeting of stockholders.
• ·Mr. McKhann holds a B.A. in Political Science and an M.B.A. from Stanford University.
• ·Standard indemnification agreement executed; no Item 404(a) related transactions.

21-04-2026

Federal Agricultural Mortgage Corporation (Farmer Mac) appointed Mandy M. Talan, its Managing Director – Corporate Controller since June 2025, as principal accounting officer effective April 21, 2026. Ms. Talan, age 45 and a Certified Public Accountant, previously held senior roles at Fannie Mae and KPMG. No agreements, family relationships, or disclosable transactions under Item 404(a) of Regulation S-K exist.

• ·Ms. Talan served as Senior Director of Finance and Regulatory Reporting at Fannie Mae from September 2022 to May 2025.
• ·Ms. Talan was Director of Accounting Policy at Fannie Mae from June 2013 to September 2022.
• ·Ms. Talan was Audit Senior Manager at KPMG from July 2010 to June 2013.

21-04-2026

Rayonier Advanced Materials Inc. (RYAM) announced a formal strategic alternatives review process to maximize shareholder value after receiving unsolicited indications of interest, with Morgan Stanley & Co. LLC as financial advisor and Wachtell, Lipton, Rosen & Katz as legal counsel. President and CEO Scott M. Sutton resigned effective immediately, prompting the Board to establish an interim Office of the Chief Executive Officer led by four senior executives including CFO Marcus J. Moeltner. RYAM generated $1.5 billion of revenue in 2025, but there is no assurance the review will result in any transaction.

• ·Announcement dated April 20, 2026; no set timetable for strategic review completion.
• ·Board committee to support the interim OFC during the strategic review process.

21-04-2026

On April 15, 2026, PPG Industries granted performance-based Market Stock Unit (MSU) awards with a target value of $1,500,000 each to executives K. Henrik Bergstrom and Kevin Braun to align with shareholder interests over three years, while Chairman and CEO Timothy Knavish and retiring CFO Vincent Morales received none. At the 2026 Annual Meeting on April 16, 2026, shareholders elected all 12 director nominees (with some opposition, notably 15,994,919 votes against Catherine R. Smith), approved executive compensation, ratified PricewaterhouseCoopers LLP as auditors, and passed the 2026 Omnibus Incentive Plan, but rejected the shareholder proposal for an independent board chair. No financial performance declines were reported in the filing.

• ·MSUs vest on May 8, 2029, based on absolute stock price appreciation from 30-day average closing price preceding May 8, 2026; requires Adjusted Earnings Per Diluted Share threshold for FY ending December 31, 2028.
• ·Highest director opposition: Catherine R. Smith (15,994,919 against votes).
• ·Shareholder proposal for independent board chair: 59,695,284 For vs. 126,745,338 Against.

21-04-2026

Aligos Therapeutics, Inc. entered into a License Agreement with Xiamen Amoytop Biotech Co., Ltd. on April 16, 2026, granting exclusive rights to develop, manufacture, and commercialize pevifoscorvir sodium for Hepatitis B (and co-infection with Hepatitis D) in mainland China, Taiwan, Hong Kong, and Macau, in exchange for a $25M upfront payment, up to $420M in milestones, and tiered high single-digit royalties on net sales. The agreement's effectiveness is conditioned on Amoytop's shareholder approval within 45 days of signing. Amoytop assumes all development, regulatory, manufacturing, and commercialization costs and responsibilities in the territory.

• ·Royalties apply until the later of 10 years after first commercial sale, patent expiration, or loss of regulatory exclusivity in each region.
• ·Amoytop has right of first negotiation for 7 years on novel formulations or compounds with the same active ingredient in the territory.
• ·Agreement includes joint steering and development committees; technical transfer at Amoytop's cost.

21-04-2026

XMax Inc.'s indirectly wholly owned subsidiary, Xmax Beta Holdings Ltd., entered a Subscription Agreement on April 15, 2026, subscribing $5,450,000 to Preamble X Capital I, increasing its interest to more than 99.9% with a 0% management fee. Preamble X Capital I then subscribed $5,350,000 on April 17, 2026, for a 3.680% interest in a private investment fund, which acquired 258,051 shares of SpaceX Class A Common Stock by April 20, 2026. No declines or flat metrics reported in this investment update.

• ·Agreement filed as Exhibit 10.1
• ·Filing signed on April 21, 2026

21-04-2026

Howard Hughes Holdings Inc. (NYSE: HHH) appointed Marc Grandisson, former CEO of Arch Capital Group Ltd., to its Board of Directors effective May 7, 2026, as a Pershing Square appointee replacing Ben Hakim. In connection with the appointment, Grandisson is investing $10 million to purchase 1,131,273 five-year warrants with a $100 strike price, which cannot be sold, transferred, or hedged for four years. The appointment occurs ahead of the expected closing this quarter of HHH's acquisition of Vantage Group Holdings, positioning the company as a diversified holding company.

• ·Grandisson will join Pershing Square as a partner in March 2027.
• ·Arch Capital delivered 23.2% annualized TSR under Grandisson vs. 14.4% for S&P Insurance Index (Mar 2, 2018 to Oct 11, 2024).
• ·Grandisson's background includes actuarial science degree from Université Laval and MBA from Wharton.

21-04-2026

On April 17, 2026, the Boards of Directors of MGE Energy, Inc. and Madison Gas and Electric Company promoted Jared Bushek from Vice President – Chief Financial Officer and Treasurer to Executive Vice President – Chief Financial Officer and Treasurer for both companies, effective May 1, 2026. In connection with the promotion, Mr. Bushek was granted a one-time retention award of restricted stock units under the 2021 Long-Term Incentive Plan with respect to 25,000 shares of MGE Energy common stock.

• ·Retention award cliff vests on the fifth anniversary of the grant date, subject to continued employment through such date.
• ·Earlier vesting upon Mr. Bushek’s death, disability, or termination without cause or resignation for good reason within 24 months following a change in control of MGE Energy.

21-04-2026

On April 17, 2026, Cerus Corporation's board of directors adopted a new Severance Plan, entering into participation agreements with key officers including CFO Kevin D. Green, COO Vivek Jayaraman, CMO Richard Benjamin, Ph.D., and CLO Chrystal N. Jensen, superseding prior arrangements. The plan offers severance benefits upon termination without cause or good reason resignation, enhanced in change-of-control scenarios with 18-24 months base salary, 1.5-2x target bonus, COBRA premiums for 18-24 months, and full equity vesting acceleration. Outside change-of-control, executives receive 12 months salary continuation, COBRA premiums, with additional prorated bonus and vesting for Jayaraman as CEO if applicable.

• ·Severance Plan filed as Exhibit 10.1
• ·Form of participation agreement filed as Exhibit 10.2
• ·Benefits triggered within 12 months following a change of control

21-04-2026

HP Inc. held its 2026 annual stockholder meeting on April 16, 2026, where all twelve director nominees were elected with strong support (for votes ranging from 618M to 649M), Ernst & Young LLP was ratified as auditors (723M for), executive compensation was approved (603M for), and the Fifth Amended 2004 Stock Incentive Plan was approved, adding 73,600,000 shares (496M for). However, the stockholder proposal for an independent board chairman was rejected (105M for vs. 548M against). No officer departures were reported.

• ·Proxy statement filed February 25, 2026, detailing Amended 2004 Plan on pages 96-104
• ·Fiscal year ends October 31, 2026
• ·Proposal 1 director votes: Kim K.W. Rucker had lowest for votes at 618,860,860 (highest against at 35,843,716)

21-04-2026

On April 17, 2026, Aron I. Schwartz, a Class II independent director of CION Investment Corp, notified the Board that he will not stand for re-election at the 2026 Annual Meeting of Shareholders on June 25, 2026, due to other professional opportunities, with no disagreement on company operations, policies, or practices. Mr. Schwartz will continue serving on the Board and its Audit, Nominating and Corporate Governance, and Compensation Committees until the Annual Meeting. The Board approved reducing its size from eight to seven members, five independent, effective June 25, 2026.

• ·Filing submitted April 21, 2026, reporting event of April 17, 2026.
• ·Securities traded on The New York Stock Exchange.

21-04-2026

Turtle Beach Corporation (TBCH) appointed Lee Haspel and Daniela Kelley as independent directors effective April 20, 2026, with Haspel joining the Nominating and Governance Committee and Audit Committee, and Kelley to serve as Audit Committee chair after the 2026 Annual Meeting. Both directors qualify as independent under Nasdaq standards, with Kelley as an audit committee financial expert, and they will receive pro-rated standard non-employee director compensation including a $50,000 annual cash retainer, $7,500 committee retainers, and 13,880 restricted shares each under the 2023 Stock-Based Incentive Compensation Plan. The appointments fulfill commitments under the March 9, 2026 Cooperation Agreement; however, Haspel has a prior affiliation with Blue Torch Capital, LP, amid the company's exploration of potential financing with Blue Torch.

• ·Mr. Haspel was a Partner at Blue Torch Capital from 2017 through 2026, with prior roles at Fifth Street Asset Management and Halcyon Asset Management; holds B.S. from Tulane University and CFA designation.
• ·Ms. Kelley is Senior Director at UiPath, Inc., former Global Head of SOX Compliance and Director of Global Controllership; over 20 years experience, CPA, B.S. from Cornell University.
• ·Company had prior term loan with Blue Torch through August 1, 2025, and is exploring potential new financing options; Mr. Haspel retains residual interest but will not be involved in negotiations.

21-04-2026

Surf Air Mobility Inc. (SRFM) closed a registered direct offering on April 21, 2026, selling 13,318,181 shares of common stock to institutional investors including LamVen LLC at $1.10 per share and 257,353 shares to directors and officers at $1.36 per share, expecting gross proceeds of approximately $15 million before fees. As of April 17, 2026, the company had 84,315,976 shares outstanding. The offering includes a 30-day restricted period prohibiting new Common Stock issuances.

• ·Offering conducted pursuant to shelf registration statement on Form S-3 (File No. 333-291485), effective November 19, 2025
• ·Restricted period of 30 days after closing during which Company cannot issue additional Common Stock or equivalents (except Form S-8 for equity incentive plans)
• ·Common stock par value $0.0001 per share, traded on NYSE under SRFM

21-04-2026

Laird Superfood, Inc. (Buyer) has entered into a Securities Purchase Agreement dated April 21, 2026, to acquire all membership interests of Terrasoul Superfoods, LLC from Superfoods Seller LLC for a base Cash Payment of $48,000,000, subject to adjustments for Closing Cash, Closing Debt, Transaction Expenses, and Working Capital Adjustment Amount, plus a potential earn-out based on 2026 Contribution Profit. The transaction includes an Adjustment Escrow Amount of $1,500,000 and concurrent execution of an Advisory Agreement with Dennis J. Botts and Restrictive Covenant Agreements with the sellers. No negative financial impacts or declines are disclosed in the agreement.

• ·Balance Sheet Date: January 31, 2026
• ·Reorganization structured as tax-free under Section 368(a)(1)(F) of the Code and IRS Revenue Ruling 2008-18
• ·Earn-Out based on 2026 Contribution Profit (Gross Profit less Credit Card Fees, Platform Fees, and Advertising, Promotion, and Marketing Expenses per Exhibit A)

21-04-2026

Serina Therapeutics, Inc. filed an 8-K on April 21, 2026, under Items 5.02 and 5.03, attaching its Amended and Restated Bylaws, restated for SEC filing purposes only. The bylaws outline corporate offices, seal, and detailed procedures for stockholders' meetings, including strict requirements for nominations and proposals at annual meetings, such as 90-120 day advance notice periods. No officer departures or elections are specified in the provided content.

• ·Stockholder notice for nominations or proposals must be delivered 90-120 days prior to the first anniversary of the prior year's annual meeting.
• ·In cases of advanced or delayed meetings, notice must be 120 days prior to the meeting and not later than 90 days prior or 10 days after public announcement.

21-04-2026

Reborn Coffee, Inc. entered into an Amended and Restated Forbearance Agreement with Arena Investors (ASOOM and ASOP) on April 15, 2026, waiving prior defaults under 10% OID Secured Convertible Debentures issued in 2025 and restructuring repayment amid payment delays. The agreement requires an initial $400,000 payment to investors plus $25,000 to counsel by April 30, 2026, followed by $400,000 monthly payments starting May 30, 2026, and full repayment by September 30, 2026, with 70% of proceeds from any securities sales applied to the debt. No operational or financial performance metrics were reported, highlighting ongoing liquidity challenges.

• ·Agreement requires filing a registration statement within 20 business days after the 10-K for shares underlying warrants issued December 31, 2025, and prior Forbearance Agreement.
• ·Prior Forbearance Agreement dated March 31, 2026; Debentures issued February 10, 2025, February 26, 2025, March 28, 2025, and July 31, 2025.
• ·Forbearance terminates upon default, insolvency, or bankruptcy events.

21-04-2026

Digital Brands Group, Inc. entered into an At-the-Market Issuance Sales Agreement with Aegis Capital Corp. on April 15, 2026, enabling the issuance and sale of common stock with an aggregate offering price of up to $100,000,000 through at-the-market offerings. The sales agent will receive a 2.0% commission on gross proceeds from any sales. The offering is subject to limitations, including not exceeding one-third of the aggregate market value of non-affiliate held common stock in any 12-month period if below $75,000,000.

• ·Agreement dated April 15, 2026; prospectus supplement filed same day.
• ·Pursuant to effective shelf registration on Form S-3 (No. 333-291361), filed November 7, 2025, effective November 26, 2025.
• ·Opinion on validity of shares by Lucosky Brookman LLP filed as Exhibit 5.1.